Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.

被引：1
|
作者：
Vire, Berengere [1 ]
Perry, Justin S. A. [2 ]
Lee, Elinor [1 ]
Stennett, Lawrence S. [1 ]
Samsel, Leigh [3 ]
McCoy, Philip [3 ]
Wilson, Wyndham H. [4 ]
Bielekova, Bibiana [2 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[2] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
[3] NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA
[4] NCI, CCR, NIH, Bethesda, MD 20892 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.1610.1610
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：643 / 644
页数：2
相关论文
共 50 条
  • [21] Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
    Winkler, U
    Jensen, M
    Manzke, O
    Tesch, H
    Bohlen, H
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 285B - 285B
  • [22] Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies
    Kozlova, Veronika
    Ledererova, Aneta
    Doubek, Michael
    Mayer, Jiri
    Pospisilova, Sarka
    Smida, Michal
    BLOOD, 2018, 132
  • [23] HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
    Shimizu, R.
    Kikuchi, J.
    Wada, T.
    Ozawa, K.
    Kano, Y.
    Furukawa, Y.
    LEUKEMIA, 2010, 24 (10) : 1760 - 1768
  • [24] HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
    R Shimizu
    J Kikuchi
    T Wada
    K Ozawa
    Y Kano
    Y Furukawa
    Leukemia, 2010, 24 : 1760 - 1768
  • [25] MODULATION OF CD20 ANTIGEN EXPRESSION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AFTER RITUXIMAB THERAPY
    D'Auria, F.
    Guariglia, R.
    Villani, O.
    Pietrantuono, G.
    Martorelli, M.
    Mansueto, G.
    Grieco, V.
    Zonno, A.
    Zifarone, E.
    Bianchino, G.
    Di Giovannantonio, L.
    Vita, G.
    Musto, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 331 - 331
  • [26] Short term in vivo activity of Rituximab anti CD20 monoclonal antibody in B-CLL patients.
    Berchem, GJ
    Heintz, D
    Bosseler, M
    Duhem, C
    Ries, F
    Dicato, MA
    BLOOD, 1999, 94 (10) : 307B - 307B
  • [27] Influence of CD20 depletion (Rituximab) on gene expression levels in patients with rheumatoid arthritis.
    Kekow, J
    Koczan, D
    Drynda, S
    Thiesen, HJ
    ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 4062 - 4062
  • [28] Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines.
    Venugopal, P
    Sivaraman, S
    Huang, X
    Chopra, HK
    O'Brein, T
    Jajeh, A
    Preisler, HD
    BLOOD, 1998, 92 (10) : 247A - 247A
  • [29] Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
    Serra-Peinado, Carla
    Grau-Exposito, Judith
    Luque-Ballesteros, Laura
    Astorga-Gamaza, Antonio
    Navarro, Jordi
    Gallego-Rodriguez, Jenny
    Martin, Mario
    Curran, Adria
    Burgos, Joaquin
    Ribera, Esteban
    Raventos, Berta
    Willekens, Rein
    Torrella, Ariadna
    Planas, Bibiana
    Badia, Rosa
    Garcia, Felipe
    Castellvi, Josep
    Genesca, Meritxell
    Falco, Vicenc
    Buzon, Maria J.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [30] Loss of CD20 Expression is an Infrequent Finding in Follicular Lymphoma Patients who Relapse Within 6 Months of Rituximab Based Therapy
    Wilding, C.
    Thompson, S.
    Mir, F.
    O'Connor, S.
    Wotherspoon, A.
    Leong, C. Chee
    Iyengar, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 90 - 90
12345